LKFT

Mechelen, Belgium; 18 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 10, 2026 and August 14, 2026, it has repurchased 107,871 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10/08/2026 XAMS 18,754 23.53 441,208.48 23.24 23.64 10/08/2026 AQEU 1 23.54 23.54 23.54 23.54 10/08/2026 CEUX 2,234 23.42 52,317.60 23.28 23.62 10/08/2026 TQEX 551 23.46 12,927.51 23.32 23.64 11/08/2026 XAMS 14,810 24.07 356,417.46 22.88 24.52 11/08/2026 CEUX 1,014 24.12 24,453.02 23.76 24.48 11/08/2026 TQEX 496 24.34 12,070.26 24.04 24.42 12/08/2026 XAMS 19,360 24.64 476,972.32 24.40 24.98 12/08/2026 AQEU 310 24.59 7,622.28 24.46 24.62 12/08/2026 CEUX 764 24.53 18,744.36 24.44 24.64 12/08/2026 TQEX 141 24.48 3,451.82 24.46 24.54 13/08/2026 XAMS 18,473 24.40 450,696.86 24.20 24.50 13/08/2026 AQEU 13 24.40 317.20 24.40 24.40 13/08/2026 CEUX 3,090 24.38 75,331.11 24.18 24.50 13/08/2026 TQEX 1,381 24.41 33,706.07 24.34 24.50 14/08/2026 XAMS 23,317 24.09 561,603.94 23.76 24.42 14/08/2026 AQEU 163 24.09 3,927.39 23.94 24.16 14/08/2026 CEUX 2,337 24.06 56,217.70 23.90 24.24 14/08/2026 TQEX 662 24.16 15,993.66 23.90 24.36 Total   107,871 24.14 2,604,002.56 22.88 24.98 As of market close on 14 August 2026, Lakefront holds 916,057 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 3, 2026 and August 7, 2026, it has repurchased 103,970 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 03/08/2026 XAMS 16,017 23.56 377,368.53 23.10 23.86 03/08/2026 CEUX 2,367 23.61 55,891.02 23.26 23.84 03/08/2026 AQEU 876 23.70 20,761.46 23.70 23.72 03/08/2026 TQEX 704 23.75 16,720.35 23.62 23.86 04/08/2026 XAMS 17,257 23.31 402,305.54 23.18 23.48 04/08/2026 CEUX 2,485 23.26 57,801.85 23.18 23.40 04/08/2026 AQEU 55 23.24 1,278.20 23.24 23.24 04/08/2026 TQEX 722 23.33 16,842.60 23.20 23.40 05/08/2026 XAMS 17,763 23.17 411,650.42 22.96 23.32 05/08/2026 CEUX 2,382 23.12 55,068.98 22.90 23.28 05/08/2026 AQEU 604 23.18 14,003.62 23.08 23.24 05/08/2026 TQEX 170 23.20 3,944.00 23.20 23.20 06/08/2026 XAMS 17,857 22.64 404,205.69 22.32 22.88 06/08/2026 CEUX 1,987 22.49 44,681.07 22.36 22.70 06/08/2026 AQEU 743 22.65 16,831.55 22.42 22.72 06/08/2026 TQEX 533 22.57 12,030.61 22.44 22.76 07/08/2026 XAMS 17,738 23.24 412,179.68 22.88 23.44 07/08/2026 CEUX 2,842 23.26 66,112.88 23.12 23.40 07/08/2026 AQEU 199 23.29 4,634.37 23.26 23.38 07/08/2026 TQEX 669 23.30 15,588.97 23.18 23.46 Total   103,970 23.18 2,409,901.40 22.32 23.86 As of market close on 07 August 2026, Lakefront holds 808,186 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 20/07/2026 XAMS 17,936 26.05 467,150.29 25.62 26.40 20/07/2026 CEUX 3,372 25.79 86,979.73 25.70 26.14 20/07/2026 AQEU 101 25.72 2,597.72 25.72 25.72 20/07/2026 TQEX 74 26.22 1,940.28 26.22 26.22 21/07/2026 XAMS 14,022 25.59 358,820.18 25.34 25.80 21/07/2026 CEUX 1,506 25.57 38,513.84 25.52 25.66 21/07/2026 AQEU 227 25.53 5,795.01 25.52 25.70 21/07/2026 TQEX 506 25.56 12,931.79 25.52 25.58 22/07/2026 XAMS 15,385 25.61 394,028.31 25.48 25.72 22/07/2026 CEUX 1,245 25.63 31,907.36 25.62 25.68 22/07/2026 AQEU 490 25.62 12,553.80 25.62 25.62 22/07/2026 TQEX 185 25.68 4,750.13 25.62 25.68 23/07/2026 XAMS 17,120 25.13 430,292.37 24.70 25.62 23/07/2026 CEUX 2,945 24.81 73,071.34 24.74 25.12 23/07/2026 AQEU 61 24.78 1,511.58 24.78 24.78 23/07/2026 TQEX 61 24.78 1,511.58 24.78 24.78 24/07/2026 XAMS 17,407 24.81 431,940.78 24.56 25.00 24/07/2026 CEUX 1,729 24.77 42,830.62 24.60 24.98 24/07/2026 AQEU 1,159 24.91 28,875.91 24.62 24.96 24/07/2026 TQEX 139 24.75 3,439.68 24.62 24.92 Total   95,670 25.41 2,431,442.30 24.56 26.40 As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 13, 2026 and July 17, 2026 it has repurchased 98,648 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 13/07/2026 XAMS 20,583 26.38 543,006.30 26.12 26.56 13/07/2026 CEUX 1,842 26.39 48,613.33 26.30 26.54 13/07/2026 AQEU 238 26.41 6,286.13 26.34 26.54 13/07/2026 TQEX 532 26.41 14,049.69 26.34 26.46 14/07/2026 XAMS 19,825 26.01 515,672.04 25.74 26.34 14/07/2026 CEUX 2,289 25.99 59,486.07 25.84 26.20 14/07/2026 AQEU 170 25.86 4,396.20 25.86 25.86 14/07/2026 TQEX 987 26.08 25,736.81 26.06 26.18 15/07/2026 XAMS 15,770 25.75 406,156.35 25.62 25.96 15/07/2026 CEUX 422 25.73 10,857.47 25.62 25.78 15/07/2026 AQEU 476 25.72 12,244.15 25.62 25.76 15/07/2026 TQEX 906 25.79 23,368.73 25.62 25.80 16/07/2026 XAMS 16,485 25.93 427,428.03 25.76 26.10 16/07/2026 CEUX 1,137 25.93 29,483.89 25.88 26.00 16/07/2026 AQEU 68 25.92 1,762.56 25.92 25.92 16/07/2026 TQEX 528 25.94 13,695.21 25.92 25.94 17/07/2026 XAMS 14,972 25.77 385,768.55 25.60 26.04 17/07/2026 CEUX 1,368 25.83 35,337.22 25.70 26.02 17/07/2026 TQEX 50 25.70 1,285.00 25.70 25.70 Total   98,648 26.00 2,564,633.73 25.60 26.56 As of market close on July 17, 2026, Lakefront holds 511,049 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 108,645 Lakefront shares between 06 July 2026 and 10 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 06/07/2026 XAMS 20,236 26.54 536,964.28 26.20 26.90 06/07/2026 CEUX 2,499 26.69 66,710.06 26.32 26.90 06/07/2026 TQEX 355 26.72 9,486.20 26.52 26.90 06/07/2026 AQEU 319 26.58 8,477.65 26.52 26.88 07/07/2026 XAMS 16,553 26.65 441,104.34 26.40 26.86 07/07/2026 CEUX 1,578 26.55 41,894.01 26.44 26.76 07/07/2026 TQEX 821 26.64 21,872.92 26.60 26.70 07/07/2026 AQEU 49 26.60 1,303.40 26.60 26.60 08/07/2026 XAMS 17,502 26.84 469,793.93 26.66 27.00 08/07/2026 CEUX 4,339 26.89 116,674.84 26.74 26.96 08/07/2026 TQEX 1,157 26.87 31,086.62 26.76 26.94 08/07/2026 AQEU 416 26.86 11,172.18 26.80 26.94 09/07/2026 XAMS 16,919 26.77 452,892.87 26.56 26.90 09/07/2026 CEUX 2,717 26.79 72,781.09 26.70 26.96 09/07/2026 TQEX 23 26.76 615.48 26.76 26.76 09/07/2026 AQEU 400 26.77 10,707.04 26.76 26.78 10/07/2026 XAMS 19,764 26.52 524,208.48 26.14 26.90 10/07/2026 CEUX 2,009 26.66 53,568.98 26.26 26.92 10/07/2026 TQEX 692 26.65 18,443.74 26.24 26.78 10/07/2026 AQEU 297 26.82 7,964.53 26.26 26.92 Total   108,645 26.67 2,897,722.65 26.14 27.00 As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.

Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 104,022 Lakefront shares between 29 June 2026 and 03 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 29/06/2026 XAMS 14,414 25.75 371,205.18 25.60 26.00 29/06/2026 CEUX 3,399 25.74 87,478.36 25.66 26.00 29/06/2026 TQEX 696 25.71 17,897.29 25.66 26.00 29/06/2026 AQEU 916 25.71 23,551.83 25.66 25.80 30/06/2026 XAMS 19,724 26.37 520,179.08 25.98 26.74 30/06/2026 CEUX 2,068 26.45 54,694.67 26.22 26.72 30/06/2026 TQEX 508 26.53 13,478.15 26.14 26.78 30/06/2026 AQEU 445 26.09 11,610.94 26.08 26.12 01/07/2026 XAMS 20,787 26.30 546,681.47 26.06 26.48 01/07/2026 CEUX 2,613 26.20 68,467.39 26.12 26.44 01/07/2026 TQEX 71 26.40 1,874.32 26.32 26.40 01/07/2026 AQEU 198 26.17 5,181.78 26.16 26.30 02/07/2026 XAMS 13,778 26.14 360,180.34 25.88 26.54 02/07/2026 CEUX 3,021 26.06 78,727.86 25.96 26.12 02/07/2026 TQEX 115 26.23 3,015.94 25.96 26.46 02/07/2026 AQEU 721 26.12 18,835.04 25.96 26.14 03/07/2026 XAMS 15,162 26.62 403,642.76 26.46 26.86 03/07/2026 CEUX 4,786 26.59 127,266.92 26.50 26.86 03/07/2026 TQEX 526 26.75 14,071.18 26.50 26.88 03/07/2026 AQEU 74 26.62 1,970.16 26.52 26.64 Total   104,022 26.24 2,730,010.70 25.60 26.88 As of market close on 03 July 2026, Lakefront holds 303,756 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 83,530 Lakefront shares between 22 June 2026 and 26 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 22/06/2026 XAMS 15,297 24.59 376,162.41 24.38 24.96 23/06/2026 XAMS 15,050 25.32 381,076.53 25.06 25.52 24/06/2026 XAMS 18,944 25.55 483,992.68 25.30 25.78 25/06/2026 XAMS 17,239 25.41 438,065.40 25.12 25.72 26/06/2026 XAMS 17,000 25.22 428,748.50 24.94 25.82 Total   83,530 25.24 2,108,045.52 24.38 25.82 As of market close on 26 June 2026, Lakefront holds 199,734 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.

Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 77,667 Lakefront shares between 15 June 2026 and 19 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 15/06/2026 EXNT 13,272 24.9331 330,912.10 24.7200 25.2200 16/06/2026 EXNT 16,400 24.5495 402,611.80 24.1200 25.2600 17/06/2026 EXNT 13,605 24.4212 332,250.43 24.0000 24.7800 18/06/2026 EXNT 16,960 24.8036 420,669.06 24.4800 25.1200 19/06/2026 EXNT 17,430 24.5966 428,718.74 24.3600 24.7600 Total   77,667 24.6586   1,915,162.13   24.3360 25.0280 As of market close on 19 June 2026, Lakefront holds 116,204 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.